ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer

被引：0
|
作者：
J. A. Kyte
A. Røssevold
R. S. Falk
B. Naume
机构：
[1] Oslo University Hospital,Department of Clinical Cancer Research
[2] Oslo University Hospital,Department of Cancer Immunology
[3] Oslo University Hospital,Department of Oncology
[4] Oslo University Hospital,Oslo Centre for Biostatistics and Epidemiology
[5] University of Oslo,Institute of Clinical Medicine
来源：
Journal of Translational Medicine | / 18卷
关键词：
Breast cancer; Triple negative; Immunotherapy; Checkpoint inhibitor; Immunogenic cell death; PD-1; PD-L1; Anthracycline; Cyclophosphamide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
    Cazzaniga, E.
    Vallini, I
    Montagna, E.
    Amoroso, D.
    Berardi, R.
    Butera, A.
    Cagossi, K.
    Cavanna, L.
    Ciccarese, M.
    Cinieri, S.
    Cretella, E.
    De Conciliis, E.
    Febbraro, A.
    Ferrau, F.
    Ferzi, A.
    Baldelli, A.
    Fontana, A.
    Gambaro, A. R.
    Garrone, O.
    Gebbia, V
    Generali, D.
    Gianni, L.
    Giovanardi, F.
    Grassadonia, A.
    Leonardi, V
    Marchetti, P.
    Sarti, S.
    Musolino, A.
    Nicolini, M.
    Putzu, C.
    Riccardi, F.
    Santini, D.
    Saracchini, S.
    Sarobba, M. G.
    Schintu, M. G.
    Scognamiglio, G.
    Spadaro, P.
    Taverniti, C.
    Toniolo, D.
    Tralongo, P.
    Turletti, A.
    Valenza, R.
    Valerio, M. R.
    Vici, P.
    Di Mauro, P.
    Cogliati, V
    Capici, S.
    Clivio, L.
    Torri, V
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (03) : 415 - 424
  • [22] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Qingyuan Zhang
    Bin Shao
    Zhongsheng Tong
    Quchang Ouyang
    Yuting Wang
    Guoying Xu
    Shaorong Li
    Huiping Li
    BMC Medicine, 20
  • [23] Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study
    M. E. Cazzaniga
    I. Vallini
    E. Montagna
    D. Amoroso
    R. Berardi
    A. Butera
    K. Cagossi
    L. Cavanna
    M. Ciccarese
    S. Cinieri
    E. Cretella
    E. De Conciliis
    A. Febbraro
    F. Ferraù
    A. Ferzi
    A. Baldelli
    A. Fontana
    A. R. Gambaro
    O. Garrone
    V. Gebbia
    D. Generali
    L. Gianni
    F. Giovanardi
    A. Grassadonia
    V. Leonardi
    P. Marchetti
    S. Sarti
    A. Musolino
    M. Nicolini
    C. Putzu
    F. Riccardi
    D. Santini
    S. Saracchini
    M. G. Sarobba
    M. G. Schintu
    G. Scognamiglio
    P. Spadaro
    C. Taverniti
    D. Toniolo
    P. Tralongo
    A. Turletti
    R. Valenza
    M. R. Valerio
    P. Vici
    P. Di Mauro
    V. Cogliati
    S. Capici
    L. Clivio
    V. Torri
    Breast Cancer Research and Treatment, 2021, 190 : 415 - 424
  • [24] Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer
    Xu Liang
    Lijun Di
    Guohong Song
    Ying Yan
    Chaoying Wang
    Hanfang Jiang
    Huiping Li
    Chinese Journal of Cancer Research, 2014, 26 (05) : 550 - 557
  • [25] Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)
    Iwata, Hiroji
    Inoue, Kenichi
    Kaneko, Koji
    Ito, Yoshinori
    Tsugawa, Koichiro
    Hasegawa, Ayumi
    Nakagawa, Shintaro
    Kuratomi, Hiroyasu
    Tamura, Kenji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (12) : 1083 - 1091
  • [26] Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer
    Liang, Xu
    Di, Lijun
    Song, Guohong
    Yan, Ying
    Wang, Chaoying
    Jiang, Hanfang
    Li, Huiping
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (05) : 550 - 557
  • [27] A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer
    Zhang, Qingyuan
    Shao, Bin
    Tong, Zhongsheng
    Ouyang, Quchang
    Wang, Yuting
    Xu, Guoying
    Li, Shaorong
    Li, Huiping
    BMC MEDICINE, 2022, 20 (01)
  • [28] Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
    Miles, D.
    Gligorov, J.
    Andre, F.
    Cameron, D.
    Schneeweiss, A.
    Barrios, C.
    Xu, B.
    Wardley, A.
    Kaen, D.
    Andrade, L.
    Semiglazov, V
    Reinisch, M.
    Patel, S.
    Patre, M.
    Morales, L.
    Patel, S. L.
    Kaul, M.
    Barata, T.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (08) : 994 - 1004
  • [29] Immunogenicity and efficacy of pembrolizumab and doxorubicin in a phase I trial for patients with metastatic triple-negative breast cancer
    Egelston, Colt A.
    Guo, Weihua
    Yost, Susan E.
    Ge, Xuan
    Lee, Jin Sun
    Frankel, Paul H.
    Cui, Yujie
    Ruel, Christopher
    Schmolze, Daniel
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Karimi, Misagh
    Somlo, George
    Lee, Peter P.
    Waisman, James R.
    Yuan, Yuan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (09) : 3013 - 3027
  • [30] Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials
    Guan, Xiuwen
    Ma, Fei
    Fan, Ying
    Zhu, Wenjie
    Hong, Ruoxi
    Xu, Binghe
    ANTI-CANCER DRUGS, 2015, 26 (08) : 894 - 901
12345